ClinicalTrials.gg
RecruitingNCT07228000Updated May 8, 2026

Bundled Cancer Screening and Genetic Services Navigation

An interventional study of Breast cancer screening navigation and Multicancer screening navigation in Breast Cancer Screening, Colon Cancer Screening and Genetics Predisposition, sponsored by Georgetown University. Recruiting at 2 sites in United States. Open to female participants aged 45 Years to 74 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by Georgetown University · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
820
Allocation
Randomized
Ages
45 Years to 74 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 87 studies in Genetic Predisposition to Disease with a site in United States — 37 open to participants now, 46 under way, none of them phase 3. Genetic Predisposition to Disease · United States.

Planned enrollment
12th of 37
820 · median 225
Started
2026
with 8 others
No phase
30 of 87
8 open now
Primary completion
2029-02
later than 26 of 45 live
Registered
80th of 87
by date

Among the 87 studies in Genetic Predisposition to Disease with a site in United States, this one is the 12th largest by planned enrollment of the 37 interventional ones that give a count, is one of 9 that started in 2026, is one of 30 with no phase, reaches primary completion later than 26 of the 45 other live ones, and was the 80th registered.

Genetic Predisposition to Disease

242 studies on the registry are indexed under Genetic Predisposition to Disease; 96 are open to participants now.

Browse Genetic Predisposition to Disease studies →

Open to participants now

37 of the 87 studies in Genetic Predisposition to Disease with a site in United States are open now. Recruiting first, the newest first:

31 more — sign in →

All 37 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 71 Genetic Predisposition to Disease studies recruiting now, 36 (51%) set no upper age limit and 28 (39%) stop at 75 or younger; 25 take children under 18; 23 take healthy volunteers.

This study: 45 Years to 74 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies in Genetic Predisposition to Disease with a site in United States, or all of them as a file.
02

Study summary

The goal of this study is to test bundled familial cancer risk assessment + multicancer (colorectal + breast) vs. single (breast) cancer navigation, using a wait list control for colorectal cancer screening referral and navigation. Among those eligible, this study will test usual care referral to genetic services vs. pretest education + usual care referral. The study also will assess how bundled multicancer navigation works and for whom it is most effective through a multisite, mixed-methods patient- and organization-level process evaluation.

Read the detailed description

Research Design and Methods:

All women referred for screening navigation within community navigation programs receive familial cancer risk assessment, bundled with either multicancer (colorectal + breast) vs. single (breast) cancer navigation, with a wait list control for colorectal cancer screening referral and navigation, stratified by site and genetics referral eligibility. Primary analyses will be conducted among those randomized to multicancer or single cancer navigation, but ineligible for genetic referral, to test effectiveness for colorectal cancer screening and non-inferiority for breast cancer screening (N=600). In exploratory subanalyses among those referred to genetic counseling based on their familial cancer risk assessment, the study will test the effect of four bundles that combine multicancer vs. single cancer navigation with usual care referral to telephone-based pretest and posttest genetic counseling and testing or video and print pre-counseling education + referral (N=180). A multi-site, mixed-methods organization- and patient-focused process evaluation is conducted alongside and at the conclusion of the trial.

Research Procedures:

Research staff not associated with navigation programs will obtain consent and HIPAA authorization, proceeding with baseline assessment and randomization, stratified by site and genetics eligibility. The trial will recruit (N=820) and retain (N=780) women to this trial within two years. N=600 are retained for primary analyses; N=180 are retained for exploratory outcomes among those referred to genetic services.

Randomization. At the end of the baseline assessment, research staff randomize participants to the single or multicancer navigation conditions, stratified by navigation site and genetic testing eligibility. Participants will be notified of study condition and connected to a navigator. Participants eligible for genetic services will receive services related to their study arm from their navigator following completion of multicancer or single cancer screening navigation. This will result in four bundles of screening and genetic services to be assessed in exploratory analyses. Contamination is mitigated through navigator training and supervision and documentation tracking. Participants will be randomized in blocks of 4 or 6 to support equal sample sizes across arms.

Navigation Protocol. Guided stepwise protocols ensure documentation and timeliness of navigation and address contamination during navigation. Steps are chronological; navigators document completion of a step to move to the next. Wait-list navigation for those in the single cancer navigation arm who have not received colorectal cancer screening by 6-months will receive colorectal cancer screening referral and navigation at this time.

03

Conditions studied

  • Breast Cancer Screening
  • Colon Cancer Screening
  • Genetics Predisposition

Keywords

  • navigation
  • mammography
  • colonoscopy
  • Fecal Immunochemical Test
  • genetic testing
  • risk assessment
04

Who can participate

Ages eligible
45 Years to 74 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Seeking screening navigation services through programs at a participating site (Georgetown Lombardi Cancer Center or Helen F. Graham Cancer Center \& Research Institutes)
  2. Eligible for breast cancer screening while also due and eligible for colorectal cancer screening (per USPSTF guidelines)
  3. Female sex
  4. Aged 45-74
  5. Identify as Black/African American race and/or Hispanic/Latin(e)(a) ethnicity
  6. Speak English or Spanish with enough fluency to complete study activities
  7. Stated willingness to comply with all study procedures (navigation, surveys) and availability for the duration of the study
  8. Provision of completed electronic form

Exclusion criteria

Exclusion Criteria:

  1. Not engaged with or planning to use navigation programs at Georgetown Lombardi Cancer Center and Helen F. Graham Cancer Center \& Research Institute
  2. Not eligible for breast cancer screening or not due and eligible for colorectal cancer screening (per USPSTF guidelines)
  3. History of breast and/or colorectal cancer; or Reporting symptoms related to breast and/or colorectal cancer (e.g., GI bleeding, breast mass)
  4. Male sex, Intersex, or other sex
  5. Under age 45 or over age 74
  6. Identifies as neither Black/African American race nor Hispanic/Latin(e)(a) ethnicity
  7. Speaks neither English nor Spanish with enough fluency to complete study activities
  8. Stated unwillingness to comply with study procedures (navigation, surveys) or unavailability for the duration of the study
  9. Inability to provide electronic , or needing another person to authorize informed consent on their behalf
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
820 participants (estimated)

Study arms

  • Experimental
    Usual care breast cancer screening navigation

    Behavioral: Breast cancer screening navigation

  • Experimental
    Multicancer screening navigation

    Behavioral: Multicancer screening navigation

  • Experimental
    Usual care breast cancer screening navigation + usual care genetic referral

    Behavioral: Breast cancer screening navigation · Behavioral: Usual care genetics referral

  • Experimental
    Usual care breast cancer screening navigation + pretest education/usual care genetic referral

    Behavioral: Breast cancer screening navigation · Behavioral: Pretest education + usual care genetics referral

  • Experimental
    Multicancer screening navigation + usual care genetic referral

    Behavioral: Multicancer screening navigation · Behavioral: Usual care genetics referral

  • Experimental
    Multicancer screening navigation + pretest education/usual care genetic referral

    Behavioral: Multicancer screening navigation · Behavioral: Pretest education + usual care genetics referral

Interventions

  • BehavioralBreast cancer screening navigation

    Single cancer navigation includes the following, oriented to breast cancer only: cancer education, barrier assessment and resolution, screening exam scheduling, text and mail reminders, documentation of appointment completion and results communicated to patient.

  • BehavioralMulticancer screening navigation

    Multi-cancer navigation includes the following, oriented to breast and colorectal cancers: cancer education, barrier assessment and resolution, screening exam scheduling, text and mail reminders, documentation of appointment completion and results communicated to patient.

  • BehavioralUsual care genetics referral

    Referral for genetics will be provided at the completion of the navigation call.

  • BehavioralPretest education + usual care genetics referral

    Print education regarding the genetic counseling and testing process and specific tips to support at-home testing. Referral for genetics will be provided at the completion of the navigation call.

06

What researchers measure

Primary outcomes

  1. Receipt of colorectal cancer screening

    Colorectal cancer screening will be determined through electronic health records abstraction. Documentation of screening includes the test (FIT, colonoscopy), date, clinical indication, assessment or result (imaging, pathology) and recommendations and procedures as applicable, following to treatment initiation.

    Time frame: 6 months after navigation completion

  2. Receipt of breast cancer screening

    Breast cancer screening (mammography, tomosynthesis, MRI, breast ultrasound, breast biopsy) will be determined through electronic health records abstraction. Documentation of screening includes the test, date, clinical indication, assessment or result (imaging, pathology) and recommendations and procedures as applicable, following to treatment initiation.

    Time frame: Six months after completion of navigation

Other outcomes

  1. Receipt of genetic testing

    Receipt of genetic testing as well as posttest genetic counseling within 6 months of randomization; documentation of test, test result, date, will be drawn from electronic health records

    Time frame: Six months after completion of navigation

  2. Receipt of genetic counseling

    Documented attendance/date of pretest genetic counseling appointment within 6 months of randomization

    Time frame: Six months after completion of navigation

07

Study locations

2 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Feb 2029, 33 months after the start.

Of 57 non-industry interventional studies with no phase under Genetic Predisposition to Disease, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 128. This study's planned 33 months is close to that.

Counting every sponsor, half of 57 studies reached it within 36 months; a quarter within 18 and three quarters within 128.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2025
First posted
Nov 13, 2025
StartActual
May 6, 2026
Primary completionEst.
Feb 28, 2029
CompletionEst.
May 31, 2029
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07228000
Responsible party
Sponsor
First posted
Nov 13, 2025
Start date
May 6, 2026
Primary completion
Feb 28, 2029 (estimated)
Completion
May 31, 2029 (estimated)
Last update
May 8, 2026

Study contacts

Suzanne O'Neill, PhD
Contact
sco4@georgetown.edu
202-687-0869
Chiranjeev Dash, PhD
Contact
cd422@georgetown.edu
202-687-1542

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion